The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Clinical outcomes associated with azacitidine (AZA) monotherapy for treatment-naïve, higher-risk myelodysplastic syndrome (HR-MDS): A systematic literature review and meta-analysis.
 
Ken Hasegawa
Employment - Gilead Sciences
Stock and Other Ownership Interests - Gilead Sciences
 
Andrew H. Wei
Honoraria - Abbvie/Genentech; Amgen; Astellas Pharma; AstraZeneca; Celgene; Janssen Oncology; Macrogenics; Novartis; Pfizer; SERVIER
Consulting or Advisory Role - Abbvie/Genentech; Amgen; Astellas Pharma; AstraZeneca; Celgene; Janssen; Macrogenics; Novartis; Pfizer; SERVIER
Speakers' Bureau - Abbvie/Genentech; Celgene/Bristol-Myers Squibb; Novartis
Research Funding - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); Celgene (Inst); Novartis (Inst); Roche (Inst); Servier (Inst)
Patents, Royalties, Other Intellectual Property - AW is a former employee of the Walter and Eliza Hall Institute which receives milestone and royalty payments related to venetoclax, and is eligible for benefits related to these payments. AW receives payments from WEHI related to venetoclax
 
Guillermo Garcia-Manero
Honoraria - Abbvie; Acceleron Pharma; Astex Pharmaceuticals; Bristol-Myers Squibb/Celgene; Curis; Genentech; Gilead Sciences; Novartis
Consulting or Advisory Role - Acceleron Pharma; Astex Pharmaceuticals; Bristol-Myers Squibb
Research Funding - Abbvie; Aprea Therapeutics; Astex Pharmaceuticals; Bristol-Myers Squibb; Curis; Genentech; Gilead Sciences; Novartis
 
Naval Guastad Daver
Consulting or Advisory Role - Abbvie; Agios; Amgen; Arog; Astellas Pharma; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; Genentech; Gilead Sciences; Immunogen; Jazz Pharmaceuticals; Novartis; Pfizer; SERVIER; Shattuck Labs; Syndax; Trillium Therapeutics
Research Funding - Abbvie; Amgen; Astellas Pharma; Bristol-Myers Squibb; Daiichi Sankyo; FATE Therapeutics; Genentech; Gilead Sciences; Glycomimetics; Hanmi; Immunogen; Novimmune; Pfizer; Servier; Trillium Therapeutics; Trovagene
 
Nishanthan Rajakumaraswamy
Employment - Gilead Sciences
Stock and Other Ownership Interests - Gilead Sciences
Patents, Royalties, Other Intellectual Property - Gilead Sciences
 
Shahed Iqbal
Employment - Gilead Sciences
Stock and Other Ownership Interests - Gilead Sciences
 
Rebecca J. Chan
No Relationships to Disclose
 
Hao Hu
Employment - Gilead Sciences
Stock and Other Ownership Interests - Gilead Sciences
 
Preston Tse
No Relationships to Disclose
 
Jiajun Yan
Employment - Roche
 
Michael J. Zoratti
No Relationships to Disclose
 
Feng Xie
Consulting or Advisory Role - Gilead Sciences
 
David Andrew Sallman
Consulting or Advisory Role - Abbvie; Bluebird Bio; Bristol-Myers Squibb; Gilead Sciences; Intellia Therapeutics; Janssen; Kite, a Gilead company; Magenta Therapeutics; Molecular Partners; Novartis; Servier; Shattuck Labs; Syndax; Syros Pharmaceuticals; Takeda
Speakers' Bureau - Bristol-Myers Squibb; Incyte; SERVIER
Research Funding - Aprea Therapeutics (Inst); Jazz Pharmaceuticals